Difference between revisions of "Part:BBa K3582028"
Sailleshac (Talk | contribs) |
|||
(One intermediate revision by the same user not shown) | |||
Line 9: | Line 9: | ||
*3] BBA_K3582023(The cyclotide precursor): The gene containing the cyclotide Kalata B1(29 amino acids), which is inserted between the C intein and the N intein so that it will circularize after translation. | *3] BBA_K3582023(The cyclotide precursor): The gene containing the cyclotide Kalata B1(29 amino acids), which is inserted between the C intein and the N intein so that it will circularize after translation. | ||
**Strep Ⅱ tag (inbuilt): This tag is placed within loop 3 of the cyclotide construct which could reduce the hemolytic activity of the cyclotide. This tag is also used to purify the molecule. | **Strep Ⅱ tag (inbuilt): This tag is placed within loop 3 of the cyclotide construct which could reduce the hemolytic activity of the cyclotide. This tag is also used to purify the molecule. | ||
− | *4] | + | *4] BBa_K3582027: Inhibitory sequence 2, which is thought to be able to inhibit the interaction between ICAM-1 and PfEMP1, is grafted into loop 6 of the cyclotide. This inhibitor has a higher affinity for interaction as compared to the wild type. |
*5] BBa_K3582021: Bsa 1 recognition site | *5] BBa_K3582021: Bsa 1 recognition site | ||
*6] BBa_K3582022: N intein, which is the modified version of the biobrick used by the Heidelberg 2014 team for circularization of the protein. | *6] BBa_K3582022: N intein, which is the modified version of the biobrick used by the Heidelberg 2014 team for circularization of the protein. | ||
Line 22: | Line 22: | ||
<span class='h3bb'>Sequence and Features</span> | <span class='h3bb'>Sequence and Features</span> | ||
<partinfo>BBa_K3582028 SequenceAndFeatures</partinfo> | <partinfo>BBa_K3582028 SequenceAndFeatures</partinfo> | ||
+ | ===References=== | ||
+ | *1] Gould, A., Ji, Y., Aboye, T. L., & Camarero, J. A. (2011, December). Cyclotides, a novel ultrastable polypeptide scaffold for drug discovery. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3330703/ | ||
+ | *2] DJ;, P. A. (n.d.). Cyclotides as grafting frameworks for protein engineering and drug design applications. Retrieved from https://pubmed.ncbi.nlm.nih.gov/23893608/ | ||
+ | *3] Camarero, J. A., & Campbell, M. J. (2019, April 19). The Potential of the Cyclotide Scaffold for Drug Development. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631875/ | ||
Latest revision as of 08:57, 24 October 2020
Inhibitory sequence 2 for PfEMP1-ICAM1 interaction grafted into a cyclotide
This biobrick is able to synthesize the grafted cyclotide that could inhibit the 5MZA interaction between the host protein (ICAM-1) and the parasite protein (PfEMP1). The different components of this biobrick are described below:
- 1] BBa_K3582020: C intein, which is the modified version of the biobrick used by the 2014 iGEM Heidelberg team.
- 2] BBa_K2333015: Bsa 1 Reversed recognition site.
- 3] BBA_K3582023(The cyclotide precursor): The gene containing the cyclotide Kalata B1(29 amino acids), which is inserted between the C intein and the N intein so that it will circularize after translation.
- Strep Ⅱ tag (inbuilt): This tag is placed within loop 3 of the cyclotide construct which could reduce the hemolytic activity of the cyclotide. This tag is also used to purify the molecule.
- 4] BBa_K3582027: Inhibitory sequence 2, which is thought to be able to inhibit the interaction between ICAM-1 and PfEMP1, is grafted into loop 6 of the cyclotide. This inhibitor has a higher affinity for interaction as compared to the wild type.
- 5] BBa_K3582021: Bsa 1 recognition site
- 6] BBa_K3582022: N intein, which is the modified version of the biobrick used by the Heidelberg 2014 team for circularization of the protein.
This final product is thought to be able to act like a drug that is capable of preventing the ICAM-1 and PfEMP1 interaction.
Sequence and Features
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal AgeI site found at 112
- 1000INCOMPATIBLE WITH RFC[1000]Illegal BsaI site found at 143
Illegal BsaI.rc site found at 109
References
- 1] Gould, A., Ji, Y., Aboye, T. L., & Camarero, J. A. (2011, December). Cyclotides, a novel ultrastable polypeptide scaffold for drug discovery. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3330703/
- 2] DJ;, P. A. (n.d.). Cyclotides as grafting frameworks for protein engineering and drug design applications. Retrieved from https://pubmed.ncbi.nlm.nih.gov/23893608/
- 3] Camarero, J. A., & Campbell, M. J. (2019, April 19). The Potential of the Cyclotide Scaffold for Drug Development. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631875/